Patient Preferences for SSc-ILD Treatment

• Research type

  Research Study

• Full title

  Patient Preferences for SSc-ILD Treatment

• IRAS ID

  271639

• Contact name

  Sebastian Heidenreich

• Contact email

  sebastian.heidenreich@evidera.com

• Sponsor organisation

  Boehringer Ingelheim International GmbH

• Duration of Study in the UK

  0 years, 2 months, 3 days

• Research summary

  This study aims to understand patients preferences about treatments for SSc-ILD (Scleroderma with lung involvement). Participants will answer a one time online survey with questions asking about hypothetical treatment scenarios. The online survey will also include sociodemographic questions.

  The study will be conducted in two phases:
  - Pilot Phase: (Completed) Telephone interviews with participants to complete the online survey and obtain feedback on the content of the survey
  - Main study Phase: Participants will be recruited from the EUSTAR registry to complete an online lasting approximately 30 minutes survey at a time convenient for them.

• REC name

  East of England - Cambridgeshire and Hertfordshire Research Ethics Committee

• REC reference

  19/EE/0294

• Date of REC Opinion

  11 Nov 2019

• REC opinion

  Further Information Favourable Opinion